Clinical trial · Interventional
Camrelizumab Combined With Famitinib Malate for Treatment of Recurrent/Metastatic Cervical Cancer
A Randomized, Open-Label, Controlled, Multi-Center Phase III Clinical Study of Camrelizumab Combined With Famitinib Malate Versus Platinum-based Chemotherapy in the Treatment of Recurrent/Metastatic Cervical Cancer
- Source
- ClinicalTrials.gov
- Retrieved
- Sep 8, 2026
- Layer
- normalized (units and labels harmonized; values unchanged)
- Run
- ING-CLINICALTRIALS-20260908-000001
Summary
Brief summary (as posted)
This study is a randomized, open-label, controlled, multi-center Phase III clinical study, aimed to evaluate the efficacy and safety of camrelizumab combined with famitinib malate versus platinum-based chemotherapy in the treatment of recurrent/metastatic cervical cancer. All enrolled patients will be randomly divided into 2 groups and continuously treated until any event that meets the criteria for end of the clinical trial.
Conditions
Conditions (1)
Free-text conditions as registered, with the CancerIndex entity they were reconciled to and the match type.
| Condition (as posted) | Mapped entity | Match | Confidence |
|---|---|---|---|
| Cervical Cancer | Malignant Cervical Neoplasm | CURATED_EXACT | 0.92 |
Interventions
Interventions (2)
| Intervention | Type | Mapped drug | Match |
|---|---|---|---|
| camrelizumab； famitinib malate | Drug | — | UNRESOLVED |
| platinum-based chemotherapy | Drug | — | UNRESOLVED |
Design
Arms and outcomes
Arms (2)
- type
- EXPERIMENTAL
- label
- camrelizumab combined with famitinib malate
- interventionNames
- Drug: camrelizumab； famitinib malate
- type
- ACTIVE_COMPARATOR
- label
- platinum-based chemotherapy
- interventionNames
- Drug: platinum-based chemotherapy
Primary outcomes (2)
- measure
- Progression-free survival (PFS) assessed by the BIRC based on RECIST V1.1 criteria
- timeFrame
- up to 2 years
- measure
- Overall survival (OS)
- timeFrame
Eligibility
Eligibility (as posted)
- Sex
- Female
- Minimum age
- 18 Years
- Maximum age
- 75 Years
Show eligibility criteria text
Inclusion Criteria: 1. Female aged 18-75 years (including 18 and 75 years, calculated based on the signing date of the informed consent) 2. Histopathologically confirmed recurrent/metastatic cervical squamous cell carcinoma that cannot be radically treated by surgery, radiotherapy or chemoradiotherapy 3. No prior systemic anti-cancer therapy for recurrent/metastatic disease 4. According to RECIST v1.1 criteria, the patient must have at least one measurable lesion 5. Able to normally swallow drug tablets 6. The organ function level is good 7. Willing to participate and able to comply with research programme requirements Exclusion Criteria: 1. Has any malignancy \<5 years prior to study entry. 2. Known to have brain or meningeal metastasis 3. Known to have autoimmune disease 4. Received live vaccinations 4 weeks before randomization or during the study period
References
Publications (0)
Data not yet available